๐๏ธ Verified NIH Record โข Updated 2026-04-06
The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors (NCT04624555)
๐ข Recruiting Interventional Protocol ๐ Observational Clinical Research Sponsor: Case Comprehensive Cancer Center
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this research study is to determine whether testing of stool for a panel of markers will enable us to detect polyps and cancer compared to standard testing.
Who can join: Review the eligibility criteria below.
Location: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center โ Cleveland, Ohio
Age range: 18 Years
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center โ Cleveland, Ohio
๐ Contact the Study Coordinator
Phone: (800) 641-2422
Email: gregory.cooper@uhhospitals.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Adenocarcinoma of the Colon
- Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps โ Fairbanks, Alaska
Explore by condition: All Adenocarcinoma of the Colon clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.